공시 • Aug 26
Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025 Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025 Reported Earnings • Sep 26
Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023) Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. 공시 • May 31
Synthaverse S.A., Annual General Meeting, Jun 25, 2024 Synthaverse S.A., Annual General Meeting, Jun 25, 2024. Reported Earnings • May 23
First quarter 2024 earnings released First quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to €1.26, the stock trades at a trailing P/E ratio of 74.3x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 48% over the past three years. Reported Earnings • Apr 11
Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022) Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. New Risk • Feb 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (85% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (6.6% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (€67.6m market cap, or US$72.9m). Reported Earnings • Nov 25
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 21
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (64% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$93.9m). 공시 • May 27
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023 BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time. Reported Earnings • Apr 21
Full year 2022 earnings released Full year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €1.22, the stock trades at a trailing P/E ratio of 58.6x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total returns to shareholders of 68% over the past year. Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €1.17, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 7.5% over the past year. 공시 • Dec 02
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 5,000,000
Price\Range: PLN 5.3 Reported Earnings • Nov 09
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Reported Earnings • Sep 10
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021). Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 73% share price gain to €1.17, the stock trades at a trailing P/E ratio of 73.9x. Average trailing P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 40% over the past year. 공시 • Jun 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022 BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022, at 11:00 Central European Standard Time. Reported Earnings • May 29
First quarter 2022 earnings released First quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021). Reported Earnings • Apr 17
Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020) Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020). Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment deteriorated over the past week After last week's 25% share price decline to €1.10, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 58% over the past year. Reported Earnings • Nov 11
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020). Reported Earnings • Sep 06
Second quarter 2021 earnings released: EPS zł0.047 (vs zł0.007 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł14.5m (up 56% from 2Q 2020). Net income: zł2.96m (up zł3.38m from 2Q 2020). Profit margin: 20% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. 공시 • May 05
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment Arm BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced a private placement of 1,734,798 common shares at a price of PLN 12.33 per share for gross proceeds of PLN 21,390,059.34 on May 4, 2021. The transaction will include participation from Ipopema Securities S.A., Investment Arm. Reported Earnings • Nov 13
Third quarter 2020 earnings released: EPS zł0.001 The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses.